Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer

Xin Guan , Ruiqi Liu , Bojun Wang , Ruxin Xiong , Luying Cui , Yuanyu Liao , Yuli Ruan , Lin Fang , Xiaolin Lu , Xuefan Yu , Dan Su , Yue Ma , Tianjiao Dang , Zhuo Chen , Yuanfei Yao , Chao Liu , Yanqiao Zhang

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (6) : e1692

PDF
Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (6) : e1692 DOI: 10.1002/ctm2.1692
RESEARCH ARTICLE

Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer

Author information +
History +
PDF

Abstract

• Silencing of NLRP3 limits the GSDMD-dependent pyroptosis in colorectal cancer.

• HDAC2-mediated histone deacetylation leads to epigenetic silencing of NLRP3.

• HDAC2 suppresses the NLRP3 transcription by inhibiting the formation of H3K27ac/BRD4/p-P65 complex.

• Targeting HDAC2 activates pyroptosis and enhances therapeutic effect.

Keywords

colorectal cancer / H3K27ac / HDAC2 / NLRP3 / pyroptosis

Cite this article

Download citation ▾
Xin Guan,Ruiqi Liu,Bojun Wang,Ruxin Xiong,Luying Cui,Yuanyu Liao,Yuli Ruan,Lin Fang,Xiaolin Lu,Xuefan Yu,Dan Su,Yue Ma,Tianjiao Dang,Zhuo Chen,Yuanfei Yao,Chao Liu,Yanqiao Zhang. Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer. Clinical and Translational Medicine, 2024, 14(6): e1692 DOI:10.1002/ctm2.1692

登录浏览全文

4963

注册一个新账户 忘记密码

References

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

AI Summary AI Mindmap
PDF

140

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/